1. Medtech Insight
  2. >>Business
  3. >>R&D

Study Links Paclitaxel To Lower-Leg Amputations

 
• By Elizabeth Orr

New research links the use of stents and balloons coated with the drug paclitaxel to an increased risk of lower-leg amputation shortly following surgery. The study was conducted by Greek researcher Konstantinos Katsanos, who previously found an increased mortality risk in paclitaxel-treated patients.

Angioplasty with stent placement- 3D rendering - Illustration

Peripheral artery disease (PAD) patients who receive balloons and stents coated with the drug paclitaxel may have a higher risk of death or lower-leg amputation following surgery, a study published in the February issue of the Journal of Vascular and Interventional Radiology reports.

The study was conducted by Konstaninos Katsanos, a researcher at Patras University Hospital in Rion, Greece. Katsanos also conducted a 2018 meta-analysis that marked the first time paclitaxel was publicly linked to an increased mortality risk in PAD patients. Further research into the question has been mixed, with some studies finding a more modest connection while real-world data didn’t seem to show a relationship

More from R&D

More from Business

Tariff Pressures Creep Into Dexcom’s Margin Outlook Despite Domestic Manufacturing Shield

 
• By Shubham Singh

Dexcom’s relatively strong position amid tariff-related uncertainty is rooted in its long-standing investments in domestic manufacturing, but raw material inflation is driving cost concerns even in the face of operational efficiencies.

Subsense Develops Nonsurgical, Nanoparticle-Based Brain-Computer Interface For Neurological Disorders

 
• By Marion Webb

Neurotechnology start-up Subsense came out of stealth with $17m in seed funding to develop a nonsurgical, nanoparticle-based brain-computer interface. Medtech Insight spoke with the firm’s new neurotech lead Cyril Eleftheriou about the technology and its potentially wide applications for treating Parkinson’s, epilepsy, inner speech decoding, and more.

New Treatment For Chronic Facial Pain Could Launch By Fall 2025

 
• By Elizabeth Orr

NeuroOne is preparing to submit its OneRF Trigeminal Nerve Ablation System to the US FDA for treating trigeminal neuralgia, a chronic facial pain condition. CEO Dave Rosa told Medtech Insight that he expects a possible product launch by fall 2025.